Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism
- PMID: 20230807
- DOI: 10.1016/j.cbi.2010.03.015
Nicotine- and caffeine-mediated changes in gene expression patterns of MPTP-lesioned mouse striatum: Implications in neuroprotection mechanism
Abstract
Exposure to 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) induces dopaminergic neurodegeneration in the nigrostriatal pathway and nicotine and caffeine ameliorate neurodegenerative changes in MPTP-lesioned mouse model of Parkinson's disease (PD). The present study was undertaken to investigate the effect of nicotine and caffeine on the expression patterns of genes in the striatum of control and MPTP-treated mice to identify the differentially expressed transcripts and to assess their possible implications in neuroprotection. Mice were treated intraperitoneally with caffeine (20mg/kg) or nicotine (1mg/kg), daily, for the first 8 weeks followed by MPTP (20mg/kg) co-treatment for further 4 weeks along with respective controls. RNA was isolated from the striatum of control and treated mice; reverse transcribed separately into labeled cDNA and a mixture of equal quantities of labeled cDNA was hybridized with mouse 15k array. The expression levels of toll-interleukin-1 receptor domain-containing adaptor protein, nuclear protein-1, cathepsin B, interleukin-4 receptor, caspase 9, complement component-1, heat shock protein-1 and cytochrome c-oxidase-VIIc were validated by quantitative real-time polymerase chain reaction (qRT-PCR). MPTP differentially regulated the expression of many genes involved in apoptotic cell death, oxidative stress, cell cycle regulation, protein modification and mitochondrial dysfunction. The expression patterns of many of these transcripts were significantly restored in caffeine- and nicotine-treated mice. The results demonstrate the involvement of multiple molecular events in MPTP-induced toxicity and nicotine or caffeine-mediated neuroprotection.
2010 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Nicotine and caffeine-mediated modulation in the expression of toxicant responsive genes and vesicular monoamine transporter-2 in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype in mouse.Brain Res. 2008 May 1;1207:193-206. doi: 10.1016/j.brainres.2008.02.023. Epub 2008 Feb 21. Brain Res. 2008. PMID: 18374908
-
Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.Brain Res. 2009 Aug 4;1283:115-26. doi: 10.1016/j.brainres.2009.06.002. Epub 2009 Jun 9. Brain Res. 2009. PMID: 19520064
-
The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection.Rejuvenation Res. 2009 Jun;12(3):185-97. doi: 10.1089/rej.2009.0850. Rejuvenation Res. 2009. PMID: 19594327
-
Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease.J Neuroendocrinol. 2012 Jan;24(1):48-61. doi: 10.1111/j.1365-2826.2011.02193.x. J Neuroendocrinol. 2012. PMID: 21790809 Review.
-
MPTP as a mitochondrial neurotoxic model of Parkinson's disease.J Bioenerg Biomembr. 2004 Aug;36(4):375-9. doi: 10.1023/B:JOBB.0000041771.66775.d5. J Bioenerg Biomembr. 2004. PMID: 15377875 Review.
Cited by
-
The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.Int J Mol Sci. 2011 Jan 17;12(1):506-69. doi: 10.3390/ijms12010506. Int J Mol Sci. 2011. PMID: 21340000 Free PMC article. Review.
-
Addressing the Neuroprotective Actions of Coffee in Parkinson's Disease: An Emerging Nutrigenomic Analysis.Antioxidants (Basel). 2022 Aug 16;11(8):1587. doi: 10.3390/antiox11081587. Antioxidants (Basel). 2022. PMID: 36009304 Free PMC article. Review.
-
Nicotinic regulation of microglia: potential contributions to addiction.J Neural Transm (Vienna). 2024 May;131(5):425-435. doi: 10.1007/s00702-023-02703-9. Epub 2023 Oct 1. J Neural Transm (Vienna). 2024. PMID: 37778006 Free PMC article. Review.
-
Role of secondary mediators in caffeine-mediated neuroprotection in maneb- and paraquat-induced Parkinson's disease phenotype in the mouse.Neurochem Res. 2012 Apr;37(4):875-84. doi: 10.1007/s11064-011-0682-0. Epub 2011 Dec 27. Neurochem Res. 2012. PMID: 22201039
-
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Pharmacol Ther. 2011 Dec;132(3):280-99. doi: 10.1016/j.pharmthera.2011.07.004. Epub 2011 Jul 23. Pharmacol Ther. 2011. PMID: 21810444 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials